Evidence map›Paper›PMID 42035382›Full record

ArticleInternational journal of hematology2026

Rapid regression of a bulky cranial lesion in high-risk multiple myeloma with isatuximab-based quadruplet induction.

Shun Ito, Takahiro Namiki, Hironao Nukariya, Toshihide Endo, Yoshihisa Sugawasa, Takashi Ichinohe, Kazuya Kurihara, Takashi Hamada, Shimon Otake, Hiromichi Takahashi and 3 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shun ItoDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Tokyo, Itabashi, 173-8610, Japan.
Takahiro NamikiDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Tokyo, Itabashi, 173-8610, Japan.
Hironao NukariyaDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Tokyo, Itabashi, 173-8610, Japan.
Toshihide EndoDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Tokyo, Itabashi, 173-8610, Japan.
Yoshihisa SugawasaDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Tokyo, Itabashi, 173-8610, Japan.
Takashi IchinoheDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Tokyo, Itabashi, 173-8610, Japan.
Kazuya KuriharaDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Tokyo, Itabashi, 173-8610, Japan.
Takashi HamadaDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Tokyo, Itabashi, 173-8610, Japan.
Shimon OtakeDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Tokyo, Itabashi, 173-8610, Japan.
Hiromichi TakahashiDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Tokyo, Itabashi, 173-8610, Japan.
Hideki NakamuraDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Tokyo, Itabashi, 173-8610, Japan.
Shihoko Komine-AizawaDivision of Microbiology, Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan.
Katsuhiro MiuraDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Tokyo, Itabashi, 173-8610, Japan. miura.katsuhiro@nihon-u.ac.jp.ORCID http://orcid.org/0000-0002-1538-3804

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 77-year-old woman with newly diagnosed immunoglobulin (Ig)G-κ multiple myeloma presented with a massive cranial paraskeletal (PS) lesion (84 × 59 × 62 mm) compressing the occipital lobe. Fluorescence in situ hybridization of bone marrow aspirate revealed 1q21 gain and 17p deletion. Induction therapy with isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) was initiated to avoid emergent local intervention. The response was rapid; head computed tomography on day 28 showed an approximately 80% reduction in bidimensional measurements, with near-complete radiologic resolution by the end of the second cycle. After the third cycle, elective reconstructive cranioplasty was performed. Although a pretreatment biopsy was not feasible, the resected tissue showed no detectable plasma cells. Measurable residual disease in the bone marrow was negative (< 10

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsMultiple MyelomaAgedBortezomibDexamethasoneFemaleHumansLenalidomideBortezomibDexamethasoneLenalidomideExtramedullary diseaseIsatuximabMultiple myelomaParaskeletal lesion

Identifiers

PMID42035382

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.